MRKMerck Sharp & Dohme LLCSigning up patients
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Breast Neoplasms · Triple Negative Breast Neoplasms · HR Low-Positive/HER2-Negative Breast Neoplasms
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 2,400 (planned)
- Started
- Jun 30, 2025
- Main results expected
- Mar 23, 2033
- Fully finished
- Dec 29, 2034
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percentage of Participants with Pathological Complete Response (pCR) at the Time of Definitive Surgery
Measured over: Up to approximately 30 weeks
Event-Free Survival (EFS)
Measured over: Up to approximately 92 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06966700 · record last updated 2026-10-13 · checked 2026-11-09 15:47 UTC